Year: 2023

Super League Announces Third Quarter 2023 Financial Results

Written by Customer Service on November 14, 2023. Posted in Earnings Releases And Operating Results.

Q3 2023 Highlighted by: Record Revenue Growth, New Roblox Partnership to Boost Marketing Strategy, and the Largest Deal in Company History SANTA MONICA, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) — Super League (Nasdaq: SLE), a global leader in providing immersive experiences across the world’s largest digital social platforms, has released its third quarter 2023 financial results in the form of a shareholder letter. A webinar hosted by Ann Hand, CEO of Super League, and Clayton Haynes, CFO of Super League, will be streamed here beginning today Tuesday, November 14, 2023 at 5:00 PM Eastern Time to further discuss the results. Management Commentary by Chief Executive Officer, Ann Hand: “In the third quarter, we continued to validate the success of our business model and operational strategy, delivering record quarterly company...

ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results

Written by Customer Service on November 14, 2023. Posted in Earnings Releases And Operating Results.

Key Corporate Highlights:Progressing toward Q1-2024 initiation of a proof-of-concept clinical trial with Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD). Granted a European patent covering use of VAR 200 (2-hydroxypropyl-beta-cyclodextrin) in diabetic nephropathy/diabetic kidney disease. Nearing completion of pre-clinical requirements for GLP toxicology studies and subsequent IND submission.WESTON, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, today provides a corporate update, and reports financial results for the third quarter of 2023 ending September 30, 2023. “The...

Homology Medicines Reports Third Quarter 2023 Financial Results

Written by Customer Service on November 14, 2023. Posted in Earnings Releases And Operating Results.

– Continuing to Evaluate Strategic Options for the Company and the Pipeline of Genetic Medicines, including HMI-103 – BEDFORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today third quarter 2023 financial results and highlighted recent updates. Homology recently shared a summary of safety and efficacy data on the first dose cohort of the pheEDIT clinical trial evaluating the Company’s HMI-103 gene editing candidate for the treatment of phenylketonuria (PKU). Despite the encouraging HMI-103 clinical data, based on the current financing environment and the anticipated clinical development timeline, Homology announced in July 2023 that it would not pursue any further development of its programs, including HMI-103, and instituted a related workforce...

XWELL, Inc. Reports Third Quarter 2023 Results

Written by Customer Service on November 14, 2023. Posted in Public Companies.

XWELL, Inc. BrandsXWELL, Inc. BrandsAirport Spas Deliver Strong 39% Year-Over-Year Q3 Revenue GrowthNaples Wax Center Acquisition Accelerates Future Off-Airport Growth OpportunitiesFurther Airport Spa Expansion Internationally NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) — XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), an authority in wellness solutions for people on the go, today reported results for the third quarter ended September 30, 2023. Financial and Business Highlights:The Company’s airport XpresSpa business segment delivered revenue growth of approximately 39% versus the comparable quarter in 2022. The Company continues to focus on reducing its cost structure and simplifying its processes in order to reach profitability in 2024. The Company realized the first milestone of its out...

Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives

Written by Customer Service on November 14, 2023. Posted in Public Companies.

SAN CARLOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today reported financial results for the third quarter ended September 30, 2023, and announced that the Company is implementing a further reduction in its workforce of approximately 40% while maintaining the necessary support to continue exploring potential strategic transactions and business alternatives. “Since our founding, Atreca has leveraged a unique discovery platform to identify numerous antibodies binding novel targets in oncology, as well as infectious and autoimmune disease,” said John Orwin. “We remain focused on advancing APN-497444 through preclinical...

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

Written by Customer Service on November 14, 2023. Posted in Public Companies.

Company to host conference call on Wednesday, November 15, 2023 at 8:00 a.m. ET BOSTON and ATLANTA, Nov. 14, 2023 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (“PD”), Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the third quarter ended September 30, 2023 and highlighted recent developments. “We are very pleased with the progress of the last quarter,” noted Dr. Milton H. Werner, President and Chief Executive Officer of Inhibikase. “Our efforts to improve drug delivery for protein kinase inhibitors brought IkT-001Pro to pre-NDA stage just 15 months after opening...

OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update

Written by Customer Service on November 14, 2023. Posted in Earnings Releases And Operating Results.

Total revenue for the first nine months of 2023 was approximately $2.35 million compared to approximately $1.89 million in the first nine months of 2022 Implemented certain cash management initiatives, including restructuring U.S. operations by reducing headcount during the third quarter of 2023 Signed preferred stock purchase agreement with a potential strategic investor in October 2023 Entered into a warrant inducement agreement with an institutional investor in October 2023 Subsidiaries Curetis GmbH in Germany and Ares Genetics GmbH in Austria filed for insolvency under German and Austrian laws, respectively, in November 2023ROCKVILLE, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

Actelis Networks Reports Third Quarter 2023

Written by Customer Service on November 14, 2023. Posted in Earnings Releases And Operating Results.

FREMONT, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) — Actelis Networks, Inc. (NASDAQ: ASNS) (“Actelis” or the “Company”), a market leader in cyber-hardened, rapid deployment Hybrid-Fiber networking solutions for wide area IoT applications, today reported financial results for the fiscal third quarter and nine months ended September 30, 2023. “During the third quarter of 2023 we have seen a good level of interest in our newly launched products, that are providing solutions for rapid deployment, cost effective and secure networking for critical infrastructure for our IoT and Federal customers. We have also seen interest from several large network operators in our new solutions aiming at connecting millions of buildings and customers in multi-tenant-building (MDU)”, said Tuvia Barlev, Chairman and CEO of Actelis. “Those products are expected...

Presidio Property Trust, Inc. Announces Earnings for the Quarter Ended September 30, 2023

Written by Customer Service on November 14, 2023. Posted in Earnings Releases And Operating Results.

SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) — Presidio Property Trust, Inc. (Nasdaq: SQFT, SQFTP, SQFTW) (the “Company”), an internally managed, diversified real estate investment trust (“REIT”), today reported earnings for its quarter ended September 30, 2023. Quarter Ended September 30, 2023, Financial Results Net income attributable to the Company’s common stockholders for the three months ended September 30, 2023 was approximately $20.96 million, or $1.77 per basic and diluted share, compared to a net loss of approximately $1.30 million, or $(0.11) per basic and diluted share for the three months ended September 30, 2022. The change in net income attributable to the Company’s common stockholders was a result of:During September, the Company’s sponsored SPAC Murphy Canyon Acquisition Corp. completed its business combination...

Atico Reports Consolidated Financial Results for Third Quarter of 2023

Written by Customer Service on November 14, 2023. Posted in Earnings Releases And Operating Results.

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, Nov. 14, 2023 (GLOBE NEWSWIRE) — Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTCQX: ATCMF) today announced its financial results for the three months ended September 30, 2023, posting a net loss of $1.1 million. Production for the period at Atico’s El Roble mine totaled 3.8 million pounds (“lbs”) of copper and 2,724 ounces (“oz”) of gold in concentrate at a cash cost(1) of $1.97 per payable pound of copper(2). Fernando E. Ganoza, CEO and Director, commented, “During the quarter we saw a significant improvement in ore production and grades at El Roble when compared to previous quarters in the year. However, these operational gains were almost completely offset by strong appreciation of the Colombian peso along with weaker...

Year: 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals